Quarterly report pursuant to Section 13 or 15(d)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)

v3.22.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Aug. 19, 2021
Aug. 09, 2021
Jan. 31, 2022
Jan. 31, 2021
Jan. 31, 2022
Jan. 31, 2021
Aug. 31, 2021
Apr. 30, 2021
Intangible assets     $ 3,549,427   $ 3,549,427     $ 3,549,427
Impairment of intangible assets         0 $ 0    
Research and Development Expense     158,039 $ 174,088 436,872 $ 595,976    
Uninsured cash balances     36,356,000   36,356,000     $ 1,921,000
Proceeds from Issuance or Sale of Equity $ 70,000,000 $ 15,000,000            
Deferred offering costs             $ 8,362,137  
Underwriters' fees             7,116,445  
Selling concessions             $ 108,979  
Cell In A Box [Member]                
Intangible assets     1,549,427   1,549,427      
Diabetes License [Member]                
Intangible assets     $ 2,000,000   $ 2,000,000      
S G Austria [Member]                
Percentage investment in SG Austria     14.30%   14.30%